Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

110.53 -0.46 (-0.41%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
Why Revolution Medicines Stock Surged by 11% Today ↗
The company might become the latest biotech acquisition story soon. 
Via The Motley Fool
Topics Intellectual Property
Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗
Via Stocktwits
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗
Via Stocktwits
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗
Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32... 
Via Benzinga
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗
Via Stocktwits
Topics Government
News headline image
American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce
In a landmark shift for the American economy, the U.S. trade deficit has plummeted to its lowest level in 17 years, signaling a profound transformation in global supply chains and domestic production.... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy
LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal... 
Via MarketMinute
Topics Earnings Economy
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands... 
Via MarketMinute
Topics Economy
News headline image
3 Drug Stocks to Buy at a Discount ↗
The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider. 
Via The Motley Fool
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the... 
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every... 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
The highest-yielding stocks in the Dow are Verizon, Chevron, and Merck, but should you buy any of them? 
Via The Motley Fool
Topics Stocks
News headline image
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations. 
Via Stocktwits
Topics Government
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations
As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Generating Yield in a Sideways Market: The Strategic Rise of Dow Jones Covered Call ETFs
As the financial markets cross the threshold into 2026, investors find themselves navigating a complex landscape defined by "tariff-driven" volatility and a shift toward earnings-justified valuations.... 
Via MarketMinute
Topics ETFs Economy Regulatory Compliance
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Top gainers and losers in the S&P500 index during Monday's after-hours session. ↗
Wondering what's happening in today's after-hours session with S&P500 stocks? Stay tuned for the latest updates on movers and shakers. 
Via Chartmill
News headline image
The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns
As the final trading days of 2025 draw to a close, the financial world finds itself standing on a high-altitude plateau that few predicted and many fear. The S&P 500 (INDEXSP: .INX) enters 2026 trading... 
Via MarketMinute
Topics Artificial Intelligence Bonds Earnings
News headline image
3 Drug Stocks to Buy at a Discount ↗
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.